日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2

阿那曲唑芳香化酶抑制剂血浆药物浓度全基因组关联研究：SLC38A7 和 ALPPL2 之间的功能上位性相互作用

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.1359
Dudenkov, Tanda M; Liu, Duan; Cairns, Junmei; Devarajan, Sandhya; Zhuang, Yongxian; Ingle, James N; Buzdar, Aman U; Robson, Mark E; Kubo, Michiaki; Batzler, Anthony; Barman, Poulami; Jenkins, Gregory D; Carlson, Erin E; Goetz, Matthew P; Northfelt, Donald W; Moreno-Aspitia, Alvaro; Desta, Zeruesenay; Reid, Joel M; Kalari, Krishna R; Wang, Liewei; Weinshilboum, Richard M
LPP
ALPP
发表日期：2019
文献求助 收藏

Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19.

药物基因组学下一代DNA测序：从CYP2C9和CYP2C19中未知意义变异体的鉴定和功能表征中汲取的经验教训

期刊:Drug Metabolism and Disposition
影响因子:4
doi:10.1124/dmd.118.084269
Devarajan Sandhya, Moon Irene, Ho Ming-Fen, Larson Nicholas B, Neavin Drew R, Moyer Ann M, Black John L, Bielinski Suzette J, Scherer Steven E, Wang Liewei, Weinshilboum Richard M, Reid Joel M
其它
药物研究
发表日期：2019
文献求助 收藏

A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)

一项针对难治性或复发性实体瘤儿童的新型微管靶向化疗药物甲磺酸艾立布林 (E7389) 的 1 期研究：儿童肿瘤协作组 1 期联盟研究 (ADVL1314)

期刊:Pediatric Blood & Cancer
影响因子:2.3
doi:10.1002/pbc.27066
Schafer, Eric S; Rau, Rachel E; Berg, Stacey; Liu, Xiaowei; Minard, Charles G; D'Adamo, David; Scott, Rachael; Reyderman, Larisa; Martinez, Gresel; Devarajan, Sandhya; Reid, Joel M; Fox, Elizabeth; Weigel, Brenda J; Blaney, Susan M
肿瘤
肿瘤免疫
发表日期：2018
文献求助 收藏